SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW YORK CITY -- ...

WASHINGTON, DC—An exploratory analysis of the PROTECTED TAVR trial suggests that use of the Sentinel cerebral embolic protection system (Boston Scientific) during TAVI had a greater impact in patients ...

The first day at the recently concluded Transcatheter Cardiovascular Therapies (TCT) meeting in Washington, D.C., was reportedly heavily focused on TAVR - transcatheter aortic valve replacement ...

TCT 319: Short -Term Clinical Effect of Cerebral Embolic Protection Device Following Transcatheter Aortic-Valve Replacement in Korea Population: The Sentinel Registry (Sentinel) Receive the the latest ...

Please provide your email address to receive an email when new articles are posted on . In patients having TAVR, cerebral embolic protection reduced risk for periprocedural stroke in patients from the ...

Only CEP Trial Designed as a Superiority Trial using DW-MRI to Demonstrate Effectiveness Against the Currently Approved Sentinel Device NEW YORK & AACHEN, Germany–(BUSINESS WIRE)–April 2, 2024– ...